CO2024001686A2 - Anticuerpos anti-vegfr1 y sus usos - Google Patents

Anticuerpos anti-vegfr1 y sus usos

Info

Publication number
CO2024001686A2
CO2024001686A2 CONC2024/0001686A CO2024001686A CO2024001686A2 CO 2024001686 A2 CO2024001686 A2 CO 2024001686A2 CO 2024001686 A CO2024001686 A CO 2024001686A CO 2024001686 A2 CO2024001686 A2 CO 2024001686A2
Authority
CO
Colombia
Prior art keywords
vegfr1
antibodies
vegfr1 antibodies
polynucleotides
antigen
Prior art date
Application number
CONC2024/0001686A
Other languages
English (en)
Inventor
Ronald V Swanson
Matthew D Breyer
Villalobos Romer A Gonzalez
Jingjun Li
Thomas J Rutkoski
Gang Zheng
Songmao Zheng
Xirong Zheng
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CO2024001686A2 publication Critical patent/CO2024001686A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente descripción se describen anticuerpos o fragmentos de unión al antígeno de estos que se unen al receptor 1 del factor de crecimiento endotelial vascular (VEGFR1), polinucleótidos, vectores, células huésped y métodos para tratar la enfermedad renal crónica usando los mismos.
CONC2024/0001686A 2021-08-16 2024-02-16 Anticuerpos anti-vegfr1 y sus usos CO2024001686A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163233343P 2021-08-16 2021-08-16
US202263322273P 2022-03-22 2022-03-22
PCT/US2022/074891 WO2023023465A1 (en) 2021-08-16 2022-08-12 Anti-vegfr1 antibodies and their uses

Publications (1)

Publication Number Publication Date
CO2024001686A2 true CO2024001686A2 (es) 2024-02-26

Family

ID=85239767

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0001686A CO2024001686A2 (es) 2021-08-16 2024-02-16 Anticuerpos anti-vegfr1 y sus usos

Country Status (11)

Country Link
EP (1) EP4388011A1 (es)
JP (1) JP2024534034A (es)
KR (1) KR20240046239A (es)
AU (1) AU2022331414A1 (es)
CA (1) CA3229430A1 (es)
CL (1) CL2024000445A1 (es)
CO (1) CO2024001686A2 (es)
IL (1) IL310840A (es)
MX (1) MX2024002112A (es)
TW (1) TW202315888A (es)
WO (1) WO2023023465A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
TW201517916A (zh) * 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途
US20220306762A1 (en) * 2019-07-03 2022-09-29 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用

Also Published As

Publication number Publication date
KR20240046239A (ko) 2024-04-08
CA3229430A1 (en) 2023-02-23
EP4388011A1 (en) 2024-06-26
TW202315888A (zh) 2023-04-16
IL310840A (en) 2024-04-01
MX2024002112A (es) 2024-05-03
WO2023023465A1 (en) 2023-02-23
CL2024000445A1 (es) 2024-08-23
JP2024534034A (ja) 2024-09-18
AU2022331414A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
CO2018014413A2 (es) Anticuerpos anti-c5 y usos de los mismos
ECSP19087580A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
CO2017013235A2 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral ox40
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
PE20191813A1 (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
EA201791121A1 (ru) Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3
EA201692459A1 (ru) Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
CR20120454A (es) Proteínas terapéuticas de unión a dll4
PE20211660A1 (es) Neoantigenos prostaticos y sus usos
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CL2022000142A1 (es) Proteínas que comprenden dominios de unión a antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CL2024000378A1 (es) Anticuerpos anti-npr1 y usos de los mismos.
CL2021000146A1 (es) Anticuerpos humanizados contra psma
CO2024002244A2 (es) Anticuerpos anti-psma y usos de estos
EA201892440A1 (ru) Антитела к tl1a и их применения
UY39436A (es) Proteínas de unión específicas y sus usos
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
CL2022003320A1 (es) Proteínas que comprenden dominios de unión al antígeno cd3 y usos de las mismas.